Vanderbilt University Medical Center, Nashville, TN 37232-2358, USA.
Trends Pharmacol Sci. 2011 Dec;32(12):734-9. doi: 10.1016/j.tips.2011.07.006. Epub 2011 Aug 29.
The renin-angiotensin-aldosterone system (RAAS) is inappropriately activated in obesity. In individuals at risk for diabetes, RAAS inhibition protects against kidney and heart disease, and also reduces the incidence of diabetes in large clinical trials. At a cellular level, angiotensin II (Ang II) and aldosterone induce insulin resistance by increasing oxidative stress and altering insulin signaling, leading to decreased glucose transport. Ang II also contributes to oxidative stress, inflammation, and apoptosis in pancreatic β cells. Aldosterone diminishes glucose-stimulated insulin secretion in vivo and in vitro from isolated pancreatic islets and cultured β cells through a mineralocorticoid receptor (MR)-independent mechanism. We review these findings in the context of pharmacological strategies interrupting the RAAS to highlight the potential application of these strategies to the prevention of diabetes progression.
肾素-血管紧张素-醛固酮系统(RAAS)在肥胖中被不恰当地激活。在有患糖尿病风险的个体中,RAAS 抑制可预防肾脏和心脏疾病,并在大型临床试验中降低糖尿病的发病率。在细胞水平上,血管紧张素 II(Ang II)和醛固酮通过增加氧化应激和改变胰岛素信号来诱导胰岛素抵抗,导致葡萄糖转运减少。Ang II 还可导致胰腺β细胞中的氧化应激、炎症和细胞凋亡。醛固酮通过一种非盐皮质激素受体(MR)独立机制,降低体内和离体胰岛和培养的β细胞中葡萄糖刺激的胰岛素分泌。我们在中断 RAAS 的药理策略的背景下审查这些发现,以强调这些策略在预防糖尿病进展中的潜在应用。